- Common MS treatment wears off more quickly in Black patients
- A less expensive, more convenient treatment option for MS?
- Investigational drug reduces brain lesions in highly active MS
- Evobrutinib may lower nerve damage biomarker levels
- Disease progression and therapy response vary in MS by ethnicity
- Some MS treatments may heighten COVID risk
- Natalizumab postinfusion reactions